News

Dr. Reddy’s Laboratories announces the launch of Bupropion HCI in the U.S. Market

Dr.-Reddy-Laboratories

Dr. Reddy’s Laboratories Ltd announced today that it has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Dr.-Reddy-LaboratoriesWellbutrin SR (bupropion HCl) Sustained-Release Tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).

The Wellbutrin SR brand and generic had U.S. sales of approximately $109.6 million MAT for the most recent twelve months ending in July 2016 according to IMS Health.

Dr. Reddy’s Buproprion SR tablets are available in 100 mg, 150 mg and 200 mg, in bottle count sizes of 60, 100 and 500.

Wellbutrin SR is a registered trademark of the GSK group of companies.

Don't be shellfish...Share on FacebookShare on Google+Share on LinkedInShare on StumbleUponPin on PinterestTweet about this on Twitter
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top